Cardiovascular Drugs Practice Questions

Q: Which beta-blocker increases HDL-cholesterol?

Celiprolol. ### Explanation **Correct Option: A. Celiprolol** Beta-blockers typically have an adverse effect on lipid profiles, often increasing triglycerides and decreasing HDL-cholesterol (the "good" cholesterol) [2]. However, **Celiprolol** is a unique, third-generation cardioselective beta-1 antagonist with **partial beta-2 agonist activity** [1]. This intrinsic sympathomimetic activity (ISA) at beta-2 receptors promotes peripheral vasodilation and stimulates lipoprotein lipase, which leads to an **increase in HDL-cholesterol** and a reduction in triglycerides [3]. This makes it metabolically "friendly" compared to traditional beta-blockers. **Analysis of Incorrect Options:** * **B. Nebivolol:** While it is a highly selective beta-1 blocker with nitric oxide (NO)-mediated vasodilatory properties, it is generally considered **lipid-neutral** [1]. It does not significantly increase HDL. * **C. Carvedilol:** This is a non-selective beta and alpha-1 blocker. While it is metabolically superior to older drugs like Propranolol (it does not worsen insulin resistance or significantly lower HDL), it does not actively increase HDL levels like Celiprolol [1]. * **D. Metoprolol:** A standard second-generation cardioselective beta-1 blocker. It is notorious for traditional beta-blocker side effects, including a **decrease in HDL** and an increase in plasma triglycerides. **High-Yield Clinical Pearls for NEET-PG:** * **Metabolic Neutrality:** Third-generation beta-blockers (Celiprolol, Carvedilol, Nebivolol) are preferred in patients with Diabetes or Dyslipidemia [1]. * **ISA Property:** Drugs with Intrinsic Sympathomimetic Activity (e.g., Pindolol, Celiprolol) cause less bradycardia and fewer lipid disturbances [3]. * **Celiprolol's Unique Profile:** It is also a weak alpha-2 antagonist, further contributing to its vasodilatory effect [3]. It is often the drug of choice in patients with **Vascular Ehlers-Danlos Syndrome**.

Q: Which of the following drugs is least useful in the management of congestive cardiac failure?

Trimetazidine. **Explanation:** The management of Congestive Cardiac Failure (CCF) focuses on improving hemodynamics, reducing remodeling, and enhancing myocardial contractility [2]. **Why Trimetazidine is the correct answer:** Trimetazidine is a **metabolic modulator** (pFOX inhibitor) that shifts myocardial metabolism from fatty acid oxidation to glucose oxidation. While it is highly effective in managing **chronic stable angina** by optimizing oxygen utilization, it has no direct effect on cardiac contractility, preload, or afterload. Large-scale clinical trials have not established it as a standard therapy for the management of heart failure, making it the "least useful" among the given options. **Analysis of other options:** * **Bucindolol:** A non-selective **beta-blocker** with mild alpha-blocking properties. Beta-blockers (like Carvedilol, Metoprolol, and Bisoprolol) are a cornerstone of CCF management as they reduce remodeling and mortality [1], [2]. * **Pimobendan:** A **calcium sensitizer** and PDE3 inhibitor. It acts as an "inodilator," increasing cardiac contractility and causing vasodilation, used specifically in acute or refractory heart failure [1], [2]. * **Vesnarinone:** An **ionotropic agent** with multiple mechanisms (PDE3 inhibition and sodium channel modulation) [2]. Though its long-term use is limited by side effects, it is pharmacologically classified as a drug for heart failure. **High-Yield Clinical Pearls for NEET-PG:** * **Beta-blockers in CCF:** Only specific ones (Bisoprolol, Carvedilol, Metoprolol succinate, and Nebivolol) are proven to reduce mortality [1]. * **Inodilators:** Drugs like Milrinone and Pimobendan are used in decompensated CCF but may increase the risk of arrhythmias [2]. * **Trimetazidine Side Effect:** It can cause **Parkinsonian symptoms** (tremors, rigidity) in elderly patients, a frequent "catch" in pharmacology questions.

Q: Which angiotensin receptor blocker also has PPAR gamma activity?

Telmisartan. **Explanation:** **Telmisartan** is unique among Angiotensin II Receptor Blockers (ARBs) because it acts as a **selective partial agonist of Peroxisome Proliferator-Activated Receptor gamma (PPAR-γ)**. 1. **Why Telmisartan is correct:** Structurally, telmisartan resembles ligands that bind to PPAR-γ (a nuclear receptor primarily involved in glucose and lipid metabolism). By activating PPAR-γ, telmisartan improves insulin sensitivity, reduces glucose levels, and exerts anti-inflammatory effects. This makes it particularly beneficial for hypertensive patients with **metabolic syndrome or Type 2 Diabetes Mellitus**. 2. **Why other options are incorrect:** * **Losartan:** Known for its unique **uricosuric property** (inhibits URAT1 transporter), making it the drug of choice for hypertensive patients with Gout. It does not have significant PPAR-γ activity. * **Candesartan & Valsartan:** These are potent, selective AT1 receptor blockers but lack the structural configuration required to modulate the PPAR-γ receptor. They are primarily used for hypertension and heart failure (especially Valsartan in post-MI patients). **High-Yield Clinical Pearls for NEET-PG:** * **Longest Half-life:** Telmisartan has the longest half-life (~24 hours) among all ARBs, allowing for once-daily dosing. * **Dual Benefit:** It is often referred to as a "Metabosartan" due to its dual action on blood pressure and metabolic parameters. * **Teratogenicity:** Like ACE inhibitors, all ARBs are **contraindicated in pregnancy** (Category D) as they cause fetal renal anomalies and oligohydramnios. * **Side Effect:** Unlike ACE inhibitors, ARBs do not cause a dry cough because they do not interfere with Bradykinin metabolism.

Q: Which of the following is a Class III antiarrhythmic drug?

Amiodarone. **Explanation:** The classification of antiarrhythmic drugs is based on the **Vaughan-Williams classification**, which categorizes drugs according to their primary mechanism of action on the cardiac action potential. **A. Amiodarone (Correct):** This is a prototypical **Class III** antiarrhythmic. Class III drugs primarily act by **blocking potassium (K+) channels**, which prolongs the duration of the action potential and the effective refractory period (ERP) without significantly affecting the conduction velocity. While Amiodarone also possesses Class I, II, and IV properties, it is categorized as Class III. **B. Phenytoin:** This is a **Class Ib** antiarrhythmic. It blocks sodium (Na+) channels and is specifically used in treating digitalis-induced arrhythmias. **C. Propafenone:** This belongs to **Class Ic**. It is a potent sodium channel blocker that significantly slows conduction velocity (prolonging the QRS complex) with minimal effect on the action potential duration. **D. Pindolol:** This is a **Class II** antiarrhythmic. It is a non-selective beta-blocker with intrinsic sympathomimetic activity (ISA), used to decrease sympathetic stimulation to the heart. **High-Yield NEET-PG Pearls:** * **Class III Mnemonic:** "A Big Dirty Dog Is Scary" (**A**miodarone, **B**retylium, **D**ronedarone, **D**ofetilide, **I**butilide, **S**otalol). * **Amiodarone Side Effects:** Pulmonary fibrosis, thyroid dysfunction (hypo/hyper due to high iodine content), corneal microdeposits, and "blue-gray" skin discoloration. * **ECG Change:** Class III drugs typically cause **QT interval prolongation**, which carries a risk of Torsades de Pointes (though the risk is lower with Amiodarone compared to Sotalol).

Q: Which of the following potassium-sparing diuretics reduces cardiac mortality?

Spironolactone. The correct answer is **Spironolactone**. **1. Why Spironolactone is correct:** Spironolactone is a **Mineralocorticoid Receptor Antagonist (MRA)** [3]. In patients with heart failure, high levels of aldosterone lead to pathological cardiac remodeling, myocardial fibrosis, and collagen deposition. Spironolactone blocks these effects, thereby preventing structural damage to the heart. The landmark **RALES trial** demonstrated that adding spironolactone to standard therapy significantly reduces morbidity and mortality in patients with Heart Failure with reduced Ejection Fraction (HFrEF). Eplerenone, another MRA, shows similar mortality benefits (EMPHASIS-HF trial). Eplerenone is more selective and does not typically cause gynecomastia [1]. **2. Why the other options are incorrect:** * **Amiloride and Triamterene:** These are **epithelial sodium channel (ENaC) blockers** that act directly on the distal tubule [1]. While they are potassium-sparing diuretics, they do not antagonize the aldosterone receptor. Consequently, they do not prevent cardiac fibrosis or remodeling and have **no proven mortality benefit** in heart failure. They are primarily used to counteract potassium loss caused by thiazides or loop diuretics. **3. High-Yield NEET-PG Pearls:** * **Mechanism:** Spironolactone is a competitive antagonist of aldosterone at the late distal tubule and collecting duct [2, 3]. * **Side Effects:** The most characteristic side effect is **gynecomastia** and impotence in men (due to non-specific binding to androgen and progesterone receptors) [1]. Eplerenone is more selective and does not typically cause gynecomastia. * **Contraindication:** Avoid in patients with significant renal impairment or **hyperkalemia** (K+ > 5.0 mEq/L) [2, 3]. * **Drug of Choice:** Spironolactone is the drug of choice for **primary hyperaldosteronism (Conn’s Syndrome)** and edema associated with **liver cirrhosis**.

Question 1

Which beta-blocker increases HDL-cholesterol?

Accepted Answer

Celiprolol

Answer

Nebivolol

Answer

Carvedilol

Answer

Metoprolol

Question 2

Which of the following drugs is least useful in the management of congestive cardiac failure?

Accepted Answer

Trimetazidine

Answer

Bucindolol

Answer

Pimobendan

Answer

Vesnarinone

Question 3

Which angiotensin receptor blocker also has PPAR gamma activity?

Accepted Answer

Telmisartan

Answer

Candesartan

Answer

Valsartan

Answer

Losartan

Question 4

Which of the following inhaled gases is used to decrease pulmonary artery pressure in adults and infants?

Accepted Answer

Nitric oxide

Answer

Nitrous oxide

Answer

Nitrogen dioxide

Answer

Nitrogen

Question 5

Which of the following is a Class III antiarrhythmic drug?

Accepted Answer

Amiodarone

Answer

Phenytoin

Answer

Propafenone

Answer

Pindolol

Question 6

Which of the following drugs is NOT used for the treatment of hypertensive emergencies?

Accepted Answer

Enalapril

Answer

Phentolamine

Answer

Fenoldopam

Answer

Sodium Nitroprusside

Question 7

Which of the following statements is NOT true regarding sotalol?

Accepted Answer

It is excreted through bile following hepatic metabolism.

Answer

It is a non-selective beta-blocker.

Answer

It prolongs the action potential duration throughout the heart.

Answer

Polymorphic ventricular tachycardia is a common problem.

Question 8

An increase in heart rate and renin release seen in patients of CHF can be overcome by which of the following drugs?

Accepted Answer

Metoprolol

Answer

Minoxidil

Answer

Metolazone

Answer

Milrinone

Question 9

Which of the following potassium-sparing diuretics reduces cardiac mortality?

Accepted Answer

Spironolactone

Answer

Amiloride

Answer

Triamterene

Answer

All the above

Question 10

A 33-year-old patient with a history of asthma is being treated for symptoms of hypertension. Which of the following beta-blockers would be an appropriate therapy for this patient?

Accepted Answer

Metoprolol

Answer

Isoprenaline

Answer

Labetalol

Answer

Propranolol

Cardiovascular Drugs — MCQs

Cardiovascular Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?